Gene injection trial aims to halt blinding eye disease
NCT ID NCT07158775
Summary
This early-stage study is testing a one-time gene therapy injection (called BS01) for people with a severe form of dry age-related macular degeneration (AMD) that causes blind spots. The goal is to see if the treatment is safe and if it can help slow down or stop the progression of vision loss. The study will enroll about 40 patients to test different doses and compare results to a group that does not receive the active treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NJ Retina
RECRUITINGEdison, New Jersey, 08820, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.